PHILADELPHIA , April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at the following upcoming conferences: Needham 23 rd Annual Virtual Healthcare Conference Steven Kelly , President and Chief Executive Officer, will give a corporate... Read More

Company to prioritize CT-0525 as its anti-HER2 CAR-M product candidate and will cease further development of CT-0508 Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis Cash and cash equivalents of $77.6 million as of December 31, 2023 , combined with a restructuring of operations, including pausing development of CT-1119, expected to... Read More

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA , April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker , M.D. to the Board of Directors of the Company, effective April 1, 2024.... Read More

PHILADELPHIA , March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024 , in San Diego, California . The poster presentation... Read More

PHILADELPHIA , Feb. 28, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in the TD Cowen 44 th Annual Health Care Conference on Wednesday, March 6 th at 2:50 pm ET . An audio webcast... Read More

PHILADELPHIA , Dec. 21, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 . Steven Kelly , President and Chief Executive Officer, will make a... Read More

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors PHILADELPHIA , Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage... Read More

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting First patient expected to be treated in the first half of 2024 PHILADELPHIA , Nov. 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational... Read More

PHILADELPHIA , Nov. 22, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will participate in a fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29 at 2:35 pm... Read More

Presented updated data from Phase 1 clinical trial of CT-0508 at CAR-TCR Summit, further supporting CAR-M safety, feasibility and mechanism of action Selected clinical candidate for CT-1119, an anti-mesothelin CAR-Monocyte Presented pre-clinical proof of concept data of in vivo CAR-M, from the Company's collaboration with Moderna, at SITC Cash, cash equivalents and marketable securities of $94.1 million expected to fund... Read More

Data demonstrate feasibility, tolerability, and early efficacy of mRNA/LNP in vivo CAR-M therapy in pre-clinical models of metastatic solid tumors Proof of concept achieved for platform under the Moderna collaboration "In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy" to be presented Friday, November 3, 2023 , at 11:30 am PT PHILADELPHIA , Oct. 31, 2023 /PRNewswire/ -- Carisma... Read More

Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on... Read More

PHILADELPHIA , Sept. 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present at several upcoming investor conferences, including: H.C. Wainwright 25th Annual Global Investment Conference Steven Kelly , President and Chief Executive Officer,... Read More

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508 New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers and best overall response PHILADELPHIA , Sept. 1, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage... Read More

PHILADELPHIA , Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023 . These conferences include: 8 th Annual CAR-TCR Summit Michael Klichinsky , PharmD, PhD, Co-Founder... Read More

Dosed first patient in Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® (pembrolizumab) in patients with HER2-overexpressing solid tumors Nominated additional oncology target as part of the Company's collaboration with Moderna to develop in-vivo targeted CAR-M therapies Cash, cash equivalents and marketable securities of $117.1 million expected to fund company through 2024 PHILADELPHIA , Aug. 10, 2023... Read More

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA ® PHILADELPHIA , June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in its Phase I clinical trial that... Read More

PHILADELPHIA , June 26, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will join the Russell 2000 ® , Russell 3000 ® and Russell Microcap ® Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon... Read More

PHILADELPHIA , May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023 . These conferences include: 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Yara... Read More

PHILADELPHIA , May 8, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly , President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15 at 1:00 pm EDT in New York . A live webcast will be... Read More

PHILADELPHIA , May 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at several healthcare industry conferences in May 2023 . These conferences include: American Society of Gene & Cell Therapy (ASGCT) 26 th Annual Meeting 2023 Carisma is giving... Read More

CAMBRIDGE, Mass. / Mar 02, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s Special Meeting of Stockholders (the “Special Meeting”) held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio,... Read More

CAMBRIDGE, Mass. / Feb 21, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), in advance of the Company’s upcoming Special Meeting of Stockholders (the “Special... Read More

CAMBRIDGE, Mass. / Feb 16, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR” all proposals, including the pending merger with Carisma Therapeutics Inc. (“Carisma”), at the Company’s upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for March 2, 2023. ISS is... Read More

CAMBRIDGE, Mass. / Feb 02, 2023 / Business Wire / Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The presentation can be found at www.SesenBioandCarisma.com . Highlights of the presentation include: The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better... Read More

Company Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution if Merger is not Approved by Stockholders CAMBRIDGE, Mass. / Jan 30, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)... Read More

Company Calls Out Misrepresentations from Investor Group CAMBRIDGE, Mass. / Jan 26, 2023 / Business Wire / Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the “Investor... Read More

Schedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com , Providing Additional Information for Stockholders Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage... Read More

Highlights Expected Special Cash Dividend of Approximately $70 Million, and Upside of CVR and Ownership of Combined Company Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders. The Sesen Bio Board of Directors remains confident that the pending... Read More

Sesen Bio Stockholders Expected to Receive Approximately $70 Million Special Cash Dividend, an Increase from up to $25 Million Previously Announced Contingent Value Right to Include Proceeds of Vicineum and Other Preclinical Assets, in Addition to Previously Announced Proceeds of Roche Agreement Companies Provide Update on Engagement with Investor Group Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma),... Read More